- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01702428
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tallinn, Estonia, 10117
- GSK Investigational Site
-
Tallinn, Estonia, 13419
- GSK Investigational Site
-
Tallinn, Estonia, 10617
- GSK Investigational Site
-
Tallinn, Estonia, 13619
- GSK Investigational Site
-
Tartu, Estonia, 50106
- GSK Investigational Site
-
-
-
-
-
Espoo, Finland, 02230
- GSK Investigational Site
-
Helsinki, Finland, 00100
- GSK Investigational Site
-
Helsinki, Finland, 00930
- GSK Investigational Site
-
Jarvenpaa, Finland, 04400
- GSK Investigational Site
-
Kokkola, Finland, 67100
- GSK Investigational Site
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Pori, Finland, 28100
- GSK Investigational Site
-
Seinajoki, Finland, 60100
- GSK Investigational Site
-
Tampere, Finland, 33100
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
-
-
-
-
Durango, Mexico, 34000
- GSK Investigational Site
-
Mexico, Mexico, 04530
- GSK Investigational Site
-
-
-
-
-
San Juan, Puerto Rico, 00936-5067
- GSK Investigational Site
-
-
-
-
-
Castellón, Spain, 12004
- GSK Investigational Site
-
Castellón, Spain, 12530
- GSK Investigational Site
-
L'Eliana, Valencia, Spain, 46183
- GSK Investigational Site
-
Quart De Poblet, Valencia, Spain, 46930
- GSK Investigational Site
-
Valencia, Spain, 46017
- GSK Investigational Site
-
Valencia, Spain, 46020
- GSK Investigational Site
-
Valencia, Spain, 46011
- GSK Investigational Site
-
Valencia, Spain, 46022
- GSK Investigational Site
-
Valencia, Spain, 46200
- GSK Investigational Site
-
Valencia, Spain, 46023
- GSK Investigational Site
-
-
-
-
Alabama
-
Dothan, Alabama, United States, 36305
- GSK Investigational Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85048
- GSK Investigational Site
-
-
Arkansas
-
Fayetteville, Arkansas, United States, 72703
- GSK Investigational Site
-
-
California
-
Anaheim, California, United States, 92804
- GSK Investigational Site
-
Daly City, California, United States, 94015
- GSK Investigational Site
-
Fresno, California, United States, 93726
- GSK Investigational Site
-
Hayward, California, United States, 94545
- GSK Investigational Site
-
Los Gatos, California, United States, 95032
- GSK Investigational Site
-
Mission Hills, California, United States, 91345
- GSK Investigational Site
-
Paramount, California, United States, 90723
- GSK Investigational Site
-
Pleasanton, California, United States, 94588
- GSK Investigational Site
-
Sacramento, California, United States, 95823
- GSK Investigational Site
-
Sacramento, California, United States, 95815
- GSK Investigational Site
-
Santa Clara, California, United States, 95051
- GSK Investigational Site
-
Walnut Creek, California, United States, 94596
- GSK Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80922
- GSK Investigational Site
-
Colorado Springs, Colorado, United States, 80920
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, United States, 83686
- GSK Investigational Site
-
-
Illinois
-
Evergreen Park, Illinois, United States, 60805
- GSK Investigational Site
-
-
Iowa
-
Ames, Iowa, United States, 50010
- GSK Investigational Site
-
-
Kansas
-
Augusta, Kansas, United States, 67010
- GSK Investigational Site
-
Overland Park, Kansas, United States, 66213
- GSK Investigational Site
-
Topeka, Kansas, United States, 66604
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, United States, 71111
- GSK Investigational Site
-
-
Maryland
-
Columbia, Maryland, United States, 21045
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02130
- GSK Investigational Site
-
Fall River, Massachusetts, United States, 02721
- GSK Investigational Site
-
-
Michigan
-
Niles, Michigan, United States, 49120
- GSK Investigational Site
-
Stevensville, Michigan, United States, 49127
- GSK Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- GSK Investigational Site
-
-
New York
-
Bronx, New York, United States, 10467
- GSK Investigational Site
-
Ithaca, New York, United States, 14850
- GSK Investigational Site
-
Syracuse, New York, United States, 13210
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45245
- GSK Investigational Site
-
Cleveland, Ohio, United States, 44106
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, United States, 16505
- GSK Investigational Site
-
Hermitage, Pennsylvania, United States, 16148
- GSK Investigational Site
-
Sellersville, Pennsylvania, United States, 18960
- GSK Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- GSK Investigational Site
-
-
South Carolina
-
Barnwell, South Carolina, United States, 29812
- GSK Investigational Site
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
- GSK Investigational Site
-
-
Texas
-
Fort Worth, Texas, United States, 76107
- GSK Investigational Site
-
Houston, Texas, United States, 77070
- GSK Investigational Site
-
League City, Texas, United States, 77573
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
Tomball, Texas, United States, 77375
- GSK Investigational Site
-
-
Utah
-
Layton, Utah, United States, 84041
- GSK Investigational Site
-
Payson, Utah, United States, 84651
- GSK Investigational Site
-
Provo, Utah, United States, 84604
- GSK Investigational Site
-
Roy, Utah, United States, 84067
- GSK Investigational Site
-
Saint George, Utah, United States, 84790
- GSK Investigational Site
-
Salt Lake City, Utah, United States, 84109
- GSK Investigational Site
-
Salt Lake City, Utah, United States, 84121
- GSK Investigational Site
-
Syracuse, Utah, United States, 84075
- GSK Investigational Site
-
West Jordan, Utah, United States, 84088
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22902
- GSK Investigational Site
-
Falls Church, Virginia, United States, 22042
- GSK Investigational Site
-
Richmond, Virginia, United States, 23298
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98104
- GSK Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- GSK Investigational Site
-
Marshfield, Wisconsin, United States, 54449
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female child between 12 and 15 months of age at the time of vaccination.
- The investigator believes that the parent(s) or Legally Acceptable Representative(s) (LAR(s)) of the child, can, and will comply with the requirements of the protocol.
- Written informed consent obtained from the parent(s)/LAR(s) of the child.
- Child is in stable health as determined by investigator's clinical examination and assessment of child's medical history.
For US children only:
• Child that previously received a 3-dose series of Prevnar 13 only (i.e., no doses given as Prevnar/Prevenar), with the last dose at least 60 days prior to study entry.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine(s) during the period starting 30 days before the day of study vaccination (i.e., 30 days prior to Day 0) or planned use during the entire study period.
- Concurrently participating in another clinical study, in which the child has been or will be exposed to an investigational or a non-investigational product.
Chronic administration of immunosuppressants, or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose or any planned administration of immunosuppressive and immune-modifying drugs during the entire study.
- For corticosteroids, this will mean prednisone, ≥0.5 mg/kg/day or equivalent.
- Inhaled and topical steroids are allowed.
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination at Visit 1 and ending at Visit 2. Please Note:
- Inactivated influenza (Flu) vaccine and Haemophilus influenzae type b conjugate vaccine (Hib) vaccines may be given at any time, including the day of study vaccination (Flu and Hib vaccines must be administered at a different location than the study vaccine/s).
- Any other age appropriate vaccine may be given starting at Visit 2 and anytime thereafter.
- Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to study vaccination at Visit 1 or planned administration from the date of vaccination through the immunogenicity evaluation at Visit 2.
- History of measles, mumps, rubella, varicella/zoster and/or hepatitis A disease.
- Known exposure to measles, mumps, rubella and/or varicella/zoster during the period starting within 30 days prior to first study vaccination.
- Previous vaccination against measles, mumps, rubella, hepatitis A and/or varicella virus.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including hypersensitivity to neomycin, latex or gelatin.
- Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
- Acute disease at the time of enrollment. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection without fever.
- Active untreated tuberculosis based on medical history.
- Any other condition which, in the opinion of the investigator, prevents the child from participating in the study.
For US children only:
- Child that previously received a vaccination with heptavalent Prevnar/Prevenar (prior vaccination should be with 3 doses of Prevnar 13 only).
- Child that previously received a fourth dose of any pneumococcal conjugate vaccine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INV_MMR_L1 Group
Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0).
All US subjects are also given PCV-13 vaccine.
The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm.
HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
|
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
Other Names:
Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
|
Experimental: INV_MMR_L2 Group
Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0).
All US subjects are also given PCV-13 vaccine.
The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm.
HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
|
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
Other Names:
Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
|
Experimental: INV_MMR_L3 Group
Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0).
All US subjects are also given PCV-13 vaccine.
The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm.
HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
|
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
Other Names:
Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
|
Active Comparator: COM_MMR Group
Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0).
All US subjects are also given PCV-13 vaccine.
The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm.
HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
Pooled analysis is conducted for this group.
|
Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-measles virus antibody concentration ≥200 milli International Unit/Milliliter (mIU/mL) among subjects who were seronegative (antibody concentration <150 mIU/mL) before vaccination.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Anti-measles Virus Antibody Concentrations
Time Frame: At Day 42
|
Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) in mIU/mL.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥10 ELISA Unit/Milliliter (EU/mL) among subjects who were seronegative (antibody concentrations <5 EU/mL) before vaccination.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Anti-mumps Virus Antibody Concentration
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in EU/mL.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥10 International Unit/Milliliter (IU/mL) among subjects who were seronegative (antibody concentrations <4 IU/mL) before vaccination.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Anti-rubella Virus Antibody Concentration
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in IU/mL.
This outcome measure is applicable to reporting groups INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3 as analysis was performed on subjects who received one of the lots of INV_MMR vaccine.
|
At Day 42
|
Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR Groups
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-measles virus antibody concentration ≥200 mIU/mL among subjects who were seronegative (antibody concentration <150 mIU/mL) before vaccination.
Criteria to demonstrate an acceptable immune response for INV_MMR in terms of seroresponse rates to measles virus at Day 42: The LL of 2-sided 95% CI for the seroresponse rate for the pooled INV_MMR lots is ≥90% for antibodies to measles virus.
|
At Day 42
|
Anti-measles Virus Antibody Concentrations in Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in mIU/mL.
|
At Day 42
|
Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR Groups
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥10 EU/mL among subjects who were seronegative (antibody concentrations <5 EU/mL) before vaccination.
|
At Day 42
|
Anti-mumps Virus Antibody Concentration in Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in EU/mL.
|
At Day 42
|
Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR Groups
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥10 IU/mL among subjects who were seronegative (antibody concentrations <4 IU/mL) before vaccination.
Criteria to demonstrate an acceptable immune response for INV_MMR in terms of seroresponse rates to rubella virus at Day 42: The LL of 2-sided 95% CI for the seroresponse rate for the pooled INV_MMR lots is ≥90% for antibodies to rubella virus.
|
At Day 42
|
Anti-rubella Virus Antibody Concentration in Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in IU/mL.
|
At Day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With an Anti-Varicella Zoster Virus (VZV) Antibody Concentration Equal to or Above the Cut-off Value in US Sub-cohort of Pooled MMR Groups
Time Frame: At Day 42
|
Seroresponse was defined as post-vaccination anti-VZV antibody concentration ≥75 mIU/mL among subjects who were seronegative (antibody concentration <25 mIU/mL) before vaccination.
|
At Day 42
|
Anti-VZV Virus Antibody Concentration in US Sub-cohort of Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in mIU/mL.
|
At Day 42
|
Percentage of Subjects With an Anti-HAV Antibody Concentration Equal to or Above the Cut-off Value in US Sub-cohort of Pooled MMR Groups
Time Frame: At Day 42
|
Percentage of subjects with an Anti-HAV antibody concentration equal to or above 15 mIU/mL were reported.
|
At Day 42
|
Anti-HAV Antibody Concentrations in US Sub-cohort of Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in mIU/mL.
|
At Day 42
|
Anti-S.Pneumoniae Antibody Concentration in US Sub-cohort of Pooled MMR Groups
Time Frame: At Day 42
|
Antibody concentrations were expressed as GMCs in microgram/Milliliter (µg/mL).
|
At Day 42
|
Number of Subjects With Any Solicited Local Adverse Events (AEs)
Time Frame: During the 4-days (Days 0-3) post-vaccination period
|
Assessed solicited local AEs were pain, redness and swelling.
Any = Occurrence of the symptom regardless of intensity grade or relation to vaccination.
|
During the 4-days (Days 0-3) post-vaccination period
|
Number of Subjects With Any Solicited General AEs
Time Frame: During the 15-days (Days 0-14) post-vaccination period
|
Assessed solicited general AEs were drowsiness, irritability and loss of appetite.
Any = Occurrence of the symptom regardless of intensity grade or relation to vaccination.
|
During the 15-days (Days 0-14) post-vaccination period
|
Number of Subjects Reporting Any Fever
Time Frame: During the 43-days (Days 0-42) post-vaccination period
|
Any fever = Fever ≥ 38°C.
|
During the 43-days (Days 0-42) post-vaccination period
|
Number of Subjects Reporting Any Rash
Time Frame: During the 43-days (Days 0-42) post-vaccination period
|
Assessed were any localized or generalized rash, rash with fever, varicella-like rash, measles/rubella-like rash.
Any = Occurrence of the symptom regardless of intensity grade or relation to vaccination.
|
During the 43-days (Days 0-42) post-vaccination period
|
Number of Subjects Reporting Any MMR Specific Solicited AEs
Time Frame: During the 43-days (Days 0-42) post-vaccination period
|
Assessed MMR specific solicited AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling.
Any = Occurrence of the symptom regardless of intensity grade or relation to vaccination.
|
During the 43-days (Days 0-42) post-vaccination period
|
Number of Subjects Reporting Any Unsolicited AEs
Time Frame: During the 43-days (Days 0-42) post-vaccination period
|
Unsolicited adverse event (AE) was defined as any adverse event reported in addition to those solicited during the clinical study and also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any = Occurrence of the symptom regardless of intensity grade or relation to vaccination.
|
During the 43-days (Days 0-42) post-vaccination period
|
Number of Subjects Reporting AEs of Specific Interest
Time Frame: From Day 0 through the end of study (Day 180)
|
AEs of specific interest included new onset chronic disease (NOCD) (e.g., autoimmune disorders, asthma, type I diabetes, vasculitis, celiac disease, conditions associated with sub-acute or chronic thrombocytopenia and allergies) and AEs prompting emergency room (ER) visits.
|
From Day 0 through the end of study (Day 180)
|
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Time Frame: From Day 0 through the end of study (Day 180)
|
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity.
Any SAE = Occurrence of SAE regardless of intensity grade or relation to vaccination.
|
From Day 0 through the end of study (Day 180)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 115648
- 2011-004891-12 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Measles
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknownMeasles VaccineBurkina Faso
-
Bandim Health ProjectUnknown
-
Postgraduate Institute of Medical Education and...Unknown
-
Bandim Health ProjectHeidelberg University; Centre de Recherche en Sante de Nouna, Burkina Faso; Navrongo... and other collaboratorsUnknown
-
Serum Institute of India Pvt. Ltd.Centers for Disease Control and Prevention; University of Colorado, BoulderCompletedProphylaxis for the Measles InfectionIndia
-
Bandim Health ProjectEnrolling by invitationMortality | Measles Vaccine | Hospital Admission | Non-specific (Heterologous) Effects of VaccinesGuinea-Bissau
-
GlaxoSmithKlineCompletedMeasles; Mumps; Rubella | Measles-Mumps-Rubella VaccineUnited States, Finland, Taiwan, Estonia, Puerto Rico
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Not yet recruiting
Clinical Trials on Priorix
-
GlaxoSmithKlineCompletedVaricella | Chickenpox VaccinesRussian Federation, Romania, Czechia, Slovakia, Italy, Sweden, Poland, Greece, Norway, Lithuania
-
CHU de Quebec-Universite LavalGlaxoSmithKlineUnknown
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
GlaxoSmithKlineCompleted
-
Assistance Publique - Hôpitaux de ParisService de Bactériologie-Virologie-Hygiène, CHU Limoge; GO-CIC network (Réseau... and other collaboratorsCompleted
-
GlaxoSmithKlineWithdrawnMeasles | Rubella | Mumps | Varicella
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, PapillomavirusPanama, Mexico, Colombia
-
GlaxoSmithKlineCompletedMeasles-Mumps-RubellaTaiwan, United States, Korea, Republic of
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaGermany, Austria